Seagen Inc.
Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors

Last updated: 30 Jul 2021

Abstract:

This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.

Status:

Grant

Type:

Utility

Filling date:

15 Mar 2017

Issue date:

8 Jun 2021

Full patent description

Patent application document